Calcium channel blockers not found to increase risk of breast cancer
the ONA take:
According to findings presented at the 2014 American Heart Association Scientific in Chicago, Illinois, researchers from the Intermountain Medical Center Heart Institute in Murray, Utah, have found that women who take calcium channel blockers to treat their hypertension are not at increased risk for developing breast cancer.
Prompted by a study conducted last year at the Fred Hutchinson Cancer Research Center in Seattle, Washington, researchers conducted two studies by analyzing data from the records of more than 3,700 women ages 50 to 70 years with no history of breast cancer who had used calcium channel blockers long-term to treat their high blood pressure.
For each study, researchers compared women who had long-term use of calcium channel blockers to similar women who did not take those medications. In one study, they found a slight increase in breast cancer risk, and a 50% decreased risk in the second study.
The second study's findings were significant, but the odds of breast cancer were much lower than those observed in the study at Fred Hutchinson. As a result, the researchers recommend the continued use of calcium channel blockers to treat hypertension, thereby reducing the risk of myocardial infarction and stroke.
Women who take calcium channel blockers to treat their hypertension are not at increased risk.
Researchers analyzed the records of more than 3,700 women who had no history of breast cancer, and who had long-term use of calcium channel blocker medications to control their blood pressure. Researchers found only a minimal increase in risk in one study and a 50 percent reduced risk in a second, leading them to recommend the continued use of these important medications to help prevent heart attack and stroke.
Findings from the Intermountain Medical Center Heart Institute study will be presented at the 2014 American Heart Association Scientific in Chicago at 10:30, EST, on Wednesday, November 19.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|